Sanwa licenses DPP-4 inhibitor to Choongwae
This article was originally published in Scrip
Executive Summary
Sanwa Kagaku Kenkyusho has licensed its pipeline DPP-4 inhibitor antidiabetic SK-0403 to Choongwae Pharma for development and commercialisation in South Korea. The Japanese firm, which is part of the Japanese pharmaceutical wholesaling group Suzuken, will receive undisclosed up-front, milestone and sales-based royalties as part of the deal. SK-0403 is currently in Phase II development in Japan, where it has just been licensed to Kowa for joint development and commercialisation.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Bayer won’t split, for now; Pfizer’s next-gen ADC pipeline; oncology dominates investment but other areas grow; goodbye NASH, hello MASH; and BMS’s CEO gives his views on India.